AMP Biopharma provides analysis for upcoming company events that will impact company price. We sift through all biotech company drivers in each quarter to identify companies with the best risk/reward scenarios and provide those analyses for you. Each company we discuss will have an associated link to our evaluation.
The group of companies for this quarter are Ophthotech (OPHT), UniQure (QURE), and CytRx (CYTR).
OPHT: Ph3 Fovista data in patients with wet AMD
QURE: Ph1/2 AMT-060 high dose cohort data in patients with Hemophilia B
CYTR: Additional Ph3 Aldoxorubicin data in patients with soft tissue sarcomas